Peritoneal Carcinomatosis from Ovarian cancer | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

The peritoneum is a thin layer of tissue made up of epithelial cells. While the parietal peritoneum lines the abdominal walls, the visceral peritoneum encircles and is continuous with the internal organs, including the ovaries, in the abdominal cavity. When ovarian cancer is discovered, peritoneal metastasis is present in 75% of cases. According to a study, it is reported to occur synchronously with the primary tumor in 55% of cases and on follow-up in 45% of cases of nongynecological malignancies. When ovarian cancer is discovered, 75% of cases have already developed peritoneal metastasis. According to a study, it is reported to occur synchronously with the primary tumor in 55% of cases and on follow-up in 45% of cases of nongynecological malignancies.

Description

The peritoneum is a delicate tissue layer made up of epithelial cells. While the parietal peritoneum lines the abdominal walls, the visceral peritoneum encircles and is continuous with the organs inside the abdominal cavity, including the ovaries. The organs of the abdominal cavity are supported by it, and it acts as a conduit for blood, lymph, and nerves. There is a tiny space filled with fluid between the two layers, which reduces friction and permits them and the organs they surround to slide freely. In the presence of peritoneal carcinomatosis and epithelial ovarian cancer, the ovarian tumor releases cancer cells that float in the peritoneal fluid and adhere to the peritoneal cells. In about 75% of patients who receive an ovarian cancer diagnosis, peritoneal metastases are present. By this time, cancer cells have frequently spread widely and appear as small, white deposits on the inner surface of the parietal and visceral peritoneum. A person may still have peritoneal cancer even after having their ovaries removed. Another condition that can affect a person is primary peritoneal cancer, which manifests when cancer begins in the peritoneum's tissue. Peritoneal carcinomatosis, on the other hand, is much more common than this.

Peritoneal Carcinomatosis from Ovarian cancer (Epidemiology)

When ovarian cancer is discovered, peritoneal metastasis is present in 75% of cases. According to a study, it is reported to occur synchronously with the primary tumor in 55% of cases and on follow-up in 45% of cases of nongynecological malignancies. Primary peritoneal cancer is a rare form of cancer that mostly affects women. Extraovarian primary peritoneal carcinoma, its subtype, only affects women. The condition affects people on average between the ages of 56 and 62. Depending on the stage, the median survival time for peritoneal carcinomatosis is six months. Stage 0, Stage 1, and Stage 2 peritoneal carcinomatoses require 5 to 10 months to treat. For patients with stage 3 and stage 4 cancer, it takes two to three months. 313,959 people worldwide are expected to develop ovarian cancer in 2020. From 1990 through the middle of the 2010s, the number of new cases of ovarian cancer decreased by 1 to 2% annually. Incidence rates decreased by an additional 3% between 2014 and 2018. This encouraging trend may be attributed to the decline in the use of menopause hormone therapy and the rise in the use of oral contraceptives in the 2000s. White women have a higher risk of developing ovarian cancer than Black women do. 12,810 deaths from ovarian cancer are anticipated in the US this year. In 2020, 207,252 people will die from ovarian cancer worldwide, according to predictions. The five most frequent cause of cancer-related death for women in the US is ovarian, fallopian tube, and peritoneal cancers taken together. The death rate dropped by about 2% between the early 2000s and the middle of 2010. From 2015 to 2019, the death rates decreased at an accelerated rate of 3% annually. This decrease in the death rate is primarily attributable to fewer cases and advancements in treatment. Patients with ovarian, fallopian tube, and peritoneal cancer in the United States have an overall 5-year survival rate of 49%.

Peritoneal Carcinomatosis from Ovarian cancer -Current Market Size & Forecast Trends

The market for peritoneal carcinomatosis resulting from ovarian cancer is expected to experience significant growth. Currently, the broader peritoneal cancer market, which includes cases of peritoneal carcinomatosis, is projected to grow from approximately USD 5.9 billion in 2024 to around USD 15.9 billion by 2031, reflecting a compound annual growth rate (CAGR) of 18.2% during this period. This growth is driven by advancements in treatment modalities such as Hyperthermic Intraperitoneal Chemotherapy (HIPEC), targeted therapies, and immunotherapies, which are increasingly being utilized to manage peritoneal carcinomatosis effectively. The rising incidence of ovarian cancer and the subsequent development of peritoneal carcinomatosis further contribute to market expansion, supported by ongoing research and increased investment in personalized medicine aimed at improving patient outcomes. Overall, the market for peritoneal carcinomatosis from ovarian cancer is well-positioned for substantial growth through 2035.

When ovarian cancer is discovered, peritoneal metastasis is present in 75% of cases. A study claims that it occurs synchronously with the primary tumor in 55% of cases and on follow-up in 45% of cases of nongynecological malignancies. Primary peritoneal cancer is a rare form of cancer that mostly affects women. Extraovarian primary peritoneal carcinoma is only a subtype that only affects females. The age range of those who have the condition is 56 to 62 on average. Depending on the stage, peritoneal carcinomatosis has a median survival time of six months. Stage 0, 1, and 2 peritoneal carcinomatoses take between 5 and 10 months to treat. For patients with stage 3 and stage 4 cancer, it takes two to three months. Ovarian cancer is predicted to affect 313,959 people worldwide in 2020. From 1990 through the middle of the 2010s, the number of new cases of ovarian cancer decreased by 1 to 2% annually. The incidence rates decreased by a greater 3% between 2014 and 2018. This encouraging trend may be attributed to the decline in the use of menopause hormone therapy and the rise in the use of oral contraceptives in the 2000s. White women have a higher risk of developing ovarian cancer than Black women do. 12,810 deaths from ovarian cancer are anticipated in the US this year. In 2020, 207,252 people are expected to die from ovarian cancer worldwide. The five most frequent cancer-related deaths among women in the US are caused by ovarian, fallopian tube, and peritoneal cancers. The death rate decreased by about 2% between the beginning of the 2000s and the middle of the 2010s. From 2015 to 2019, the death rates dropped by an increased 3% annually. The primary causes of this decline in the death rate are fewer cases and advancements in treatment. Patients with ovarian, fallopian tube, and peritoneal cancers have a 49% overall 5-year survival rate in the United States.

Report Highlights

Peritoneal Carcinomatosis from Ovarian cancer - Current Market Trends

Peritoneal Carcinomatosis from Ovarian cancer - Current & Forecasted Cases across the G8 Countries

Peritoneal Carcinomatosis from Ovarian cancer - Market Opportunities and Sales Potential for Agents

Peritoneal Carcinomatosis from Ovarian cancer - Patient-based Market Forecast to 2035

Peritoneal Carcinomatosis from Ovarian cancer - Untapped Business Opportunities

Peritoneal Carcinomatosis from Ovarian cancer - Product Positioning Vis-a-vis Competitors' Products

Peritoneal Carcinomatosis from Ovarian cancer - KOLs Insight